MA50096A - Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux - Google Patents
Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non virauxInfo
- Publication number
- MA50096A MA50096A MA050096A MA50096A MA50096A MA 50096 A MA50096 A MA 50096A MA 050096 A MA050096 A MA 050096A MA 50096 A MA50096 A MA 50096A MA 50096 A MA50096 A MA 50096A
- Authority
- MA
- Morocco
- Prior art keywords
- free dna
- lipid nanoparticle
- dna vectors
- nanoparticle formulations
- viral capside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556334P | 2017-09-08 | 2017-09-08 | |
| US201762556333P | 2017-09-08 | 2017-09-08 | |
| US201762556381P | 2017-09-09 | 2017-09-09 | |
| US201862675317P | 2018-05-23 | 2018-05-23 | |
| US201862675324P | 2018-05-23 | 2018-05-23 | |
| US201862675327P | 2018-05-23 | 2018-05-23 | |
| US201862675322P | 2018-05-23 | 2018-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50096A true MA50096A (fr) | 2020-07-15 |
Family
ID=65635269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050096A MA50096A (fr) | 2017-09-08 | 2018-09-07 | Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210059953A1 (fr) |
| EP (1) | EP3679148A4 (fr) |
| JP (3) | JP2020537493A (fr) |
| KR (1) | KR102696307B1 (fr) |
| CN (1) | CN111295448A (fr) |
| AU (1) | AU2018330208B2 (fr) |
| BR (1) | BR112020004219A2 (fr) |
| CA (1) | CA3075180A1 (fr) |
| CO (1) | CO2020002262A2 (fr) |
| IL (1) | IL272799B2 (fr) |
| MA (1) | MA50096A (fr) |
| MX (1) | MX2020002501A (fr) |
| MY (1) | MY209906A (fr) |
| PH (1) | PH12020500466A1 (fr) |
| SG (1) | SG11202000765PA (fr) |
| WO (1) | WO2019051289A1 (fr) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| MA51842A (fr) * | 2018-02-14 | 2020-12-23 | Generation Bio Co | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion |
| WO2019226650A1 (fr) * | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Administration d'adn |
| WO2020033863A1 (fr) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale |
| WO2021016075A1 (fr) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Compositions à recombinase et leurs méthodes d'utilisation |
| US20220288231A1 (en) * | 2019-08-12 | 2022-09-15 | Generation Bio Co. | Methods and compositions for reducing gene or nucleic acid therapy-related immune responses |
| JP7700101B2 (ja) * | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| AU2020385378A1 (en) * | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CA3179420A1 (fr) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions d'antigenes de coronavirus et leurs utilisations |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| CA3182026A1 (fr) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Compositions a base de trem et procedes associes |
| CA3180101A1 (fr) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc | Compositions de trem et procedes associes |
| MX2023000806A (es) * | 2020-07-17 | 2023-04-11 | Generation Bio Co | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| MX2023002439A (es) | 2020-09-03 | 2023-05-09 | Flagship Pioneering Innovations Vi Llc | Composiciones immunogénicas y usos de las mismas. |
| GB202014751D0 (en) | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| IL303886A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Inc | Compositions of modified trems and uses thereof |
| WO2022155195A1 (fr) * | 2021-01-12 | 2022-07-21 | Peranteau William | Nanoparticules de lipide ionisables destinées à l'administration in utéro d'arnm |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| WO2022236016A1 (fr) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Compositions de vecteurs d'adn non viraux lyophilisées et leurs utilisations |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2023009547A1 (fr) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Compositions de trem et leurs utilisations |
| EP4124348A1 (fr) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticules pour l'administration de cellules |
| CN116179605B (zh) * | 2021-08-12 | 2025-11-11 | 蓝图生物医药(广州)有限公司 | 一种重组腺相关病毒载体及其应用 |
| ES2994006T3 (en) | 2021-09-17 | 2025-01-16 | Flagship Pioneering Innovations Vi Llc | Compositions and methods for producing circular polyribonucleotides |
| JP2024538144A (ja) | 2021-10-18 | 2024-10-18 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ポリリボヌクレオチドを精製するための組成物及び方法 |
| EP4436984A1 (fr) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes de coronavirus et leurs utilisations |
| AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| MX2024006440A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones inmunogenicas y sus usos. |
| JP2024546855A (ja) | 2021-12-17 | 2024-12-26 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 変性条件下での環状ｒｎａの濃縮方法 |
| KR20240117149A (ko) | 2021-12-22 | 2024-07-31 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법 |
| MX2024007870A (es) | 2021-12-23 | 2024-08-15 | Flagship Pioneering Innovations Vi Llc | Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos. |
| WO2023148303A1 (fr) * | 2022-02-02 | 2023-08-10 | Mslsolutions Gmbh | Procédé de production de médicaments et de vaccins |
| WO2023177655A1 (fr) * | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation |
| EP4499607A1 (fr) | 2022-03-25 | 2025-02-05 | Sail Biomedicines, Inc. | Nouveaux lipides et nanoparticules lipidiques ionisables et leurs procédés d'utilisation |
| AR128960A1 (es) * | 2022-04-04 | 2024-06-26 | Spark Therapeutics Inc | Mejoramiento inmunológico y tratamiento de enfermedades infecciosas |
| JP2025511756A (ja) | 2022-04-08 | 2025-04-16 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | ワクチン及び関連する方法 |
| US20250295687A1 (en) | 2022-05-09 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| JP2025516638A (ja) | 2022-05-13 | 2025-05-30 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 二本鎖ｄｎａ組成物及び関連する方法 |
| EP4531819A2 (fr) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation |
| US20250179492A1 (en) | 2022-06-22 | 2025-06-05 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| US12239718B2 (en) | 2022-07-12 | 2025-03-04 | Trustees Of Boston University | Synthetic cellular signaling pathways and uses thereof |
| JP2025525778A (ja) | 2022-08-01 | 2025-08-07 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 免疫調節タンパク質及び関連方法 |
| KR102544632B1 (ko) * | 2022-08-05 | 2023-06-16 | 주식회사 무진메디 | 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물 |
| EP4569112A1 (fr) | 2022-08-12 | 2025-06-18 | Remix Therapeutics Inc. | Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs |
| AU2023334610A1 (en) | 2022-08-31 | 2025-03-13 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| AU2023372397A1 (en) | 2022-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| EP4615465A1 (fr) | 2022-11-08 | 2025-09-17 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production de polyribonucléotides circulaires |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2024151583A2 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccins et procédés associés |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
| WO2024167885A1 (fr) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Compositions immunomodulatrices et procédés associés |
| IL322468A (en) | 2023-02-13 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions |
| IL322378A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA compositions containing modified cytosine |
| JP2026507513A (ja) | 2023-02-17 | 2026-03-04 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 修飾されたウラシルを含むｄｎａ組成物 |
| AU2024229184A1 (en) | 2023-03-02 | 2025-08-28 | Krystal Biotech, Inc. | Interleukin-2 and interleukin-12 for cancer therapy |
| WO2024192420A1 (fr) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides et leurs utilisations |
| EP4680276A1 (fr) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| KR102938591B1 (ko) * | 2023-04-06 | 2026-03-12 | 주식회사 무진메디 | 수분산성이 우수한 고함량 세라마이드 조성물 |
| WO2024216128A1 (fr) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems destinés à être utilisés dans la correction de mutations faux-sens |
| WO2024216191A1 (fr) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trem modifiées, compositions et procédés associés |
| WO2024220746A2 (fr) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Agents d'arni ciblant la synthase d'acides gras et procédés associés |
| WO2024258829A1 (fr) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025006684A1 (fr) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
| AU2024299627A1 (en) | 2023-07-25 | 2026-01-22 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025042786A1 (fr) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
| WO2025049632A1 (fr) * | 2023-08-29 | 2025-03-06 | Rejuvenation Technologies Inc. | Compositions et méthodes pour l'administration large d'arn dans un tissu |
| WO2025054236A2 (fr) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025052180A2 (fr) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipides et nanoparticules lipidiques |
| AU2024344058A1 (en) | 2023-09-18 | 2026-04-02 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025072331A1 (fr) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Nucléases cas et procédés ou méthodes associés |
| WO2025096807A2 (fr) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Nouvelles formes d'adn thérapeutique |
| WO2025106670A1 (fr) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025194019A1 (fr) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la fibrose hépatique et de la stéatose hépatique non alcoolique |
| WO2025217275A2 (fr) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Compositions ciblées sur des cellules immunitaires et procédés associés |
| WO2025240680A1 (fr) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Protéines inhibitrices d'immunorécepteurs et procédés associés |
| WO2025245188A2 (fr) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la stéatose hépatique et d'une stéatose hépatique non alcoolique |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026003582A2 (fr) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipides et nanoparticules lipidiques |
| WO2026055543A1 (fr) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn modifiées et procédés associés |
| WO2026055547A1 (fr) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn et procédés associés |
| WO2026064313A1 (fr) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Compositions d'arn et procédés associés |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| DE10044384A1 (de) * | 2000-09-08 | 2002-04-18 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| JP2008526229A (ja) * | 2005-01-06 | 2008-07-24 | ベニテック，インコーポレーテッド | 幹細胞の維持のためのＲＮＡｉ剤 |
| LT2816118T (lt) * | 2005-05-31 | 2018-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Genų pristatymo būdai |
| WO2008016391A2 (fr) * | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation |
| AU2016203992A1 (en) * | 2009-05-11 | 2016-06-30 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
| AU2013281328B2 (en) * | 2012-06-27 | 2017-11-23 | MeiraGTx Gene Regulation Limited | Combination for treating an inflammatory disorder |
| US9687448B2 (en) * | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| KR20210122917A (ko) * | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| KR102234672B1 (ko) * | 2013-05-21 | 2021-04-06 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 |
| EP4019506A1 (fr) * | 2013-12-19 | 2022-06-29 | Novartis AG | Lipides et compositions lipidiques pour l'administration d'agents actifs |
| EP3242945B1 (fr) * | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Construction génique à vecteur unique comprenant des gènes de l'insuline et de la glucokinase |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| WO2017152149A1 (fr) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Adn double hélice linéaire à extrémité fermée pour transfert de gène non viral |
-
2018
- 2018-09-07 AU AU2018330208A patent/AU2018330208B2/en active Active
- 2018-09-07 US US16/644,574 patent/US20210059953A1/en not_active Abandoned
- 2018-09-07 WO PCT/US2018/050042 patent/WO2019051289A1/fr not_active Ceased
- 2018-09-07 BR BR112020004219-6A patent/BR112020004219A2/pt unknown
- 2018-09-07 KR KR1020207009733A patent/KR102696307B1/ko active Active
- 2018-09-07 IL IL272799A patent/IL272799B2/en unknown
- 2018-09-07 EP EP18853914.2A patent/EP3679148A4/fr active Pending
- 2018-09-07 SG SG11202000765PA patent/SG11202000765PA/en unknown
- 2018-09-07 CA CA3075180A patent/CA3075180A1/fr active Pending
- 2018-09-07 MA MA050096A patent/MA50096A/fr unknown
- 2018-09-07 CN CN201880057740.5A patent/CN111295448A/zh active Pending
- 2018-09-07 JP JP2020512808A patent/JP2020537493A/ja active Pending
- 2018-09-07 MX MX2020002501A patent/MX2020002501A/es unknown
- 2018-09-07 MY MYPI2020000655A patent/MY209906A/en unknown
-
2020
- 2020-02-28 CO CONC2020/0002262A patent/CO2020002262A2/es unknown
- 2020-03-06 PH PH12020500466A patent/PH12020500466A1/en unknown
-
2022
- 2022-11-02 JP JP2022176366A patent/JP2023002828A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189114A patent/JP2025016593A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002501A (es) | 2020-09-17 |
| NZ761412A (en) | 2024-07-05 |
| EP3679148A4 (fr) | 2021-06-09 |
| IL272799B1 (en) | 2025-07-01 |
| WO2019051289A1 (fr) | 2019-03-14 |
| BR112020004219A2 (pt) | 2020-09-08 |
| WO2019051289A9 (fr) | 2019-05-23 |
| AU2018330208A1 (en) | 2020-02-27 |
| KR102696307B1 (ko) | 2024-08-16 |
| MY209906A (en) | 2025-08-11 |
| KR20200051708A (ko) | 2020-05-13 |
| EP3679148A1 (fr) | 2020-07-15 |
| RU2020110805A (ru) | 2021-10-11 |
| IL272799B2 (en) | 2025-11-01 |
| JP2023002828A (ja) | 2023-01-10 |
| CA3075180A1 (fr) | 2019-03-14 |
| CO2020002262A2 (es) | 2020-05-29 |
| PH12020500466A1 (en) | 2021-01-25 |
| IL272799A (en) | 2020-04-30 |
| SG11202000765PA (en) | 2020-03-30 |
| JP2025016593A (ja) | 2025-02-04 |
| RU2020110805A3 (fr) | 2022-01-19 |
| CN111295448A (zh) | 2020-06-16 |
| AU2018330208B2 (en) | 2025-04-17 |
| JP2020537493A (ja) | 2020-12-24 |
| US20210059953A1 (en) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50096A (fr) | Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux | |
| EP3877521A4 (fr) | Formulations de nanoparticules lipidiques | |
| EP3877522A4 (fr) | Formulations de nanoparticules lipidiques | |
| IL286515A (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MA49421A (fr) | Formulations d'arn | |
| IL271389A (en) | Targeted non-viral dna insertions | |
| PT3858333T (pt) | Preparação e armazenamento de formulações de arn lipossómico adequadas para terapia | |
| MA45478A (fr) | Compositions de conjugués d'acides nucléiques ciblés | |
| ES3063077T3 (en) | Lipid nanoparticle formulations | |
| EP3554558A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3723811A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| EP3518971A4 (fr) | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations | |
| MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| EP3413909A4 (fr) | Administration sous-cutanée d'adénovirus à double ciblage | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| EP3654946A4 (fr) | Formulations en poudre de cromolyne sodique et d'ibuprofène | |
| EP3442544A4 (fr) | Méthodes améliorées d'administration de gènes | |
| EP3448407A4 (fr) | Protéines dimères pour le ciblage spécifique de séquences d'acides nucléiques | |
| MA45451A (fr) | Formulations tensioactives destinées à l'inhalation | |
| EP3687559A4 (fr) | Compositions ciblant des macrophages associés à une tumeur et leurs méthodes d'utilisation | |
| HUE062806T2 (hu) | Vektorok Friedreich-ataxia kezelésére |